{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:49:29Z","timestamp":1791053369902,"version":"4.1.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2000,4,1]],"date-time":"2000-04-01T00:00:00Z","timestamp":954547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,12,24]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>The up-regulated B cell responses detectable in cerebrospinal fluid (CSF) and the augmented myelin antigen-specific T cell responses observed in the CSF as well as systematically in patients with multiple sclerosis (MS) suggest the involvement of cytokines in disease development and perpetuation. Here we report on the parallel involvement of TNF-\u03b1, IL-6, IFN-\u03b3 and IL-10 in MS and controls, using enzyme-linked immunospot (ELISPOT) assays to detect and enumerate cytokine-secreting mononuclear cells (MNC) prepared from blood and, for IL-6 and IL-10, from CSF without in\u2003vitro stimulation. MS is associated with elevated levels of TNF-\u03b1-secreting blood MNC when compared with levels in groups of control patients with myasthenia gravis (MG) and other neurological diseases (OND) or healthy subjects. This elevation was confined to patients with untreated MS and not present in those examined during ongoing treatment with IFN-\u03b2. Untreated patients with MS had lower numbers of IL-10-secreting blood MNC compared with the three control groups. In patients undergoing treatment with IFN-\u03b2, numbers of IL-10-secreting cells were in the same range as in controls. Normalization of TNF-\u03b1 from elevated, and of IL-10 from decreased levels could be one reason for the beneficial effects of IFN-\u03b2 in MS, although it remains to be shown whether these changes reflect phenomena primarily involved in MS pathogenesis or secondary changes. In CSF, levels of IL-10-secreting cells were higher than in blood in both MS and OND, with no difference between these groups. Systemic aberrations of IL-6 and IFN-\u03b3 and of IL-6 in CSF in MS versus controls were only minor, irrespective of treatment with IFN-\u03b2.<\/jats:p>","DOI":"10.1046\/j.1365-2249.2000.01175.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T10:20:51Z","timestamp":1047378051000},"page":"147-153","source":"Crossref","is-referenced-by-count":90,"title":["Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-<i>\u03b1<\/i>)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-<i>\u03b2<\/i>) treatment"],"prefix":"10.1093","volume":"120","author":[{"given":"V","family":"\u00d6zenci","sequence":"first","affiliation":[{"name":"Karolinska Institutet, Division of Neurology, Unit of Neuroimmunology, Huddinge University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kouwenhoven","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Division of Neurology, Unit of Neuroimmunology, Huddinge University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-M","family":"Huang","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Division of Neurology, Unit of Neuroimmunology, Huddinge University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Kivis\u00e4kk","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Division of Neurology, Unit of Neuroimmunology, Huddinge University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Link","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Division of Neurology, Unit of Neuroimmunology, Huddinge University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"2022011316464495300_b1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0092-8674(00)81107-1","article-title":"Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system","volume":"85","author":"Steinman","year":"1996","journal-title":"Cell"},{"key":"2022011316464495300_b2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00005072-199706000-00002","article-title":"High IL-6 and low IL-10 in the central nervous system are associated with protracted relapsing EAE in DA rats","volume":"56","author":"Diab","year":"1997","journal-title":"J Neuropathol Exp Neurol"},{"key":"2022011316464495300_b3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/(SICI)1097-4547(19960815)45:4<322::AID-JNR1>3.0.CO;2-B","article-title":"Cytokines and the pathogenesis of MS","volume":"45","author":"Navikas","year":"1996","journal-title":"J Neurosci Res"},{"key":"2022011316464495300_b4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ana.410260618","article-title":"Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis","volume":"26","author":"Franciota","year":"1989","journal-title":"Ann Neurol"},{"key":"2022011316464495300_b5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/brain\/119.1.213","article-title":"Augmented expression of tumor necrosis factor-\u03b1 and lymphotoxin mRNA in mononuclear cells in multiple sclerosis and optic neuritis","volume":"119","author":"Navikas","year":"1996","journal-title":"Brain"},{"key":"2022011316464495300_b6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0165-5728(91)90073-G","article-title":"Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis","volume":"32","author":"Maimone","year":"1991","journal-title":"J Neuroimmunol"},{"key":"2022011316464495300_b7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0165-5728(95)00155-7","article-title":"Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis","volume":"64","author":"Navikas","year":"1996","journal-title":"J Neuroimmunol"},{"key":"2022011316464495300_b8","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/eji.1830210620","article-title":"Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls","volume":"21","author":"Sun","year":"1991","journal-title":"Eur J Immunol"},{"key":"2022011316464495300_b9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ana.410360309","article-title":"Increased transforming growth factor-\u03b2, interleukin-4 and interferon-\u03b3 in multiple sclerosis","volume":"36","author":"Link","year":"1994","journal-title":"Ann Neurol"},{"key":"2022011316464495300_b10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-3083.1995.tb03550.x","article-title":"Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis","volume":"41","author":"Navikas","year":"1995","journal-title":"Scand J Immunol"},{"key":"2022011316464495300_b11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00878525","article-title":"Low serum interleukin levels in multiple sclerosis: further evidence for decreased systemic immunosuppression?","volume":"243","author":"Salmaggi","year":"1996","journal-title":"J Neurol"},{"key":"2022011316464495300_b12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(05)60303-0","article-title":"Measurements of serum cytokines","volume":"352","author":"Barnes","year":"1998","journal-title":"Lancet"},{"key":"2022011316464495300_b13","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","article-title":"Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial","volume":"45","author":"The IFNB Multiple Sclerosis Study Group.","year":"1995","journal-title":"Neurology"},{"key":"2022011316464495300_b14","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicenter randomized trial of interferon \u03b2-1b in treatment of secondary progressive multiple sclerosis","volume":"352","author":"European Study Group on Interferon \u03b2-","year":"1998","journal-title":"Lancet"},{"key":"2022011316464495300_b15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/00002826-199412000-00001","article-title":"Interferons and multiple sclerosis","volume":"154","author":"Arnason","year":"1994","journal-title":"Clin Neuropharm"},{"key":"2022011316464495300_b16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Ann Neurol"},{"key":"2022011316464495300_b17","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"2022011316464495300_b18","first-page":"497","article-title":"Studies in myasthenia gravis: review of twenty year experience in over 1200 patients","volume":"38","author":"Osserman","year":"1971","journal-title":"Mount Sinai J Med"},{"key":"2022011316464495300_b19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0022-1759(88)90079-8","article-title":"Reverse ELISPOT assay for clinical analysis of cytokine production. I. Enumeration of gamma-interferon secreting cells","volume":"110","author":"Czerkinsky","year":"1988","journal-title":"J Immunol Methods"},{"key":"2022011316464495300_b20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1172\/JCI115253","article-title":"Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls","volume":"87","author":"Link","year":"1991","journal-title":"J Clin Invest"},{"key":"2022011316464495300_b21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1046\/j.1365-3083.1999.00546.x","article-title":"Multiple sclerosis: levels of IL-10 secreting blood mononuclear cells are low in untreated patients but augmented during IFN-\u03b2-1b treatment","volume":"49","author":"\u00d6zenci","year":"1999","journal-title":"Scand J Immunol"},{"key":"2022011316464495300_b22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0022-1759(96)00170-6","article-title":"A comparison between ELISPOT methods for the detection of cytokine producing cells: greater sensitivity and specificity using ELISA plates as compared to nitrocellulose membranes","volume":"15","author":"R\u00f6nnelid","year":"1997","journal-title":"J Immunol Methods"},{"key":"2022011316464495300_b23","first-page":"903","article-title":"Direct comparison of ELISPOT and ELISA based assays for detection of individual cytokine secreting cells","volume":"12","author":"Tanguay","year":"1994","journal-title":"Lymphokine Cytokine Res"},{"key":"2022011316464495300_b24","doi-asserted-by":"crossref","first-page":"793","DOI":"10.4049\/jimmunol.150.3.793","article-title":"Detection and quantitation of cells secreting IL-6 under physiological conditions in BALB\/c mice","volume":"150","author":"Shirai","year":"1993","journal-title":"J Immunol"},{"key":"2022011316464495300_b25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1365-2249.1998.00641.x","article-title":"Quantitative intracellular cytokine measurement: age-related changes in proinflammatory cytokine production","volume":"113","author":"O\u2019Mahony","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"2022011316464495300_b26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1139\/y98-050","article-title":"Cellular response to moderate and heavy exercise","volume":"76","author":"Nehlsen-Cannarella","year":"1998","journal-title":"Can J Physiol Pharmacol"},{"key":"2022011316464495300_b27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1023\/A:1027344730553","article-title":"Effect of food restriction on life span and immune functions in long-lived Fisher-344 x Brown Norway F1 rats","volume":"17","author":"Fernandes","year":"1997","journal-title":"J Clin Immunol"},{"key":"2022011316464495300_b28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/00006842-199807000-00016","article-title":"Stressor-induced alternations of cytokine production in multiple sclerosis patients and controls","volume":"60","author":"Ackerman","year":"1998","journal-title":"Psychosom Med"},{"key":"2022011316464495300_b29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0022-510X(93)90032-T","article-title":"Interleukin-2 secreting cells in multiple sclerosis and controls","volume":"120","author":"Lu","year":"1993","journal-title":"J Neurol Sci"},{"key":"2022011316464495300_b30","first-page":"517","article-title":"Tumor necrosis factor","volume-title":"The cytokine handbook","author":"Zhang","year":"1999","edition":"3rd edn"},{"key":"2022011316464495300_b31","doi-asserted-by":"crossref","first-page":"684","DOI":"10.4049\/jimmunol.162.2.684","article-title":"Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen presenting cell-derived IL-12","volume":"162","author":"Becher","year":"1999","journal-title":"J Immunol"},{"key":"2022011316464495300_b32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0301-0082(97)00021-X","article-title":"Interleukin-6 (IL-6)\u2014a molecule with both beneficial and destructive potentials","volume":"52","author":"Gadient","year":"1997","journal-title":"Prog Neurobiol"},{"key":"2022011316464495300_b33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(96)00283-3","article-title":"IL-6 detection in multiple sclerosis brain","volume":"146","author":"Maimone","year":"1997","journal-title":"J Neuro Sci"},{"key":"2022011316464495300_b34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/intimm\/10.5.703","article-title":"IL-6 deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein","volume":"10","author":"Okuda","year":"1998","journal-title":"Int Immunol"},{"key":"2022011316464495300_b35","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0167-5699(97)01103-1","article-title":"IL-6 and AAPs: anti-inflammatory and immunosuppressive mediators","volume":"18","author":"Tilg","year":"1997","journal-title":"Immunol Today"},{"key":"2022011316464495300_b36","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1084\/jem.174.5.1209","article-title":"Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes","volume":"174","author":"De Waal Malefyt","year":"1991","journal-title":"J Exp Med"},{"key":"2022011316464495300_b37","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0165-5728(97)00264-6","article-title":"Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats","volume":"84","author":"Xiao","year":"1998","journal-title":"J Neuroimmunol"},{"key":"2022011316464495300_b38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0022-510X(97)00228-1","article-title":"Cerebrospinal fluid interleukin 6 in amyotropic parameter and comparison with inflammatory and non-inflammatory central nervous system diseases","volume":"154","author":"Sekizawa","year":"1998","journal-title":"J Neurol Sci"},{"key":"2022011316464495300_b39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0165-5728(96)00060-4","article-title":"Recombinant interferon-\u03b2 blocks proliferation but enhances interleukin-10 secretion by activated human T cells","volume":"67","author":"Rep","year":"1996","journal-title":"J Neuroimmunol"},{"key":"2022011316464495300_b40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0165-5728(95)00070-I","article-title":"Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients","volume":"61","author":"Porrini","year":"1995","journal-title":"J Neuroimmunol"},{"key":"2022011316464495300_b41","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1212\/WNL.51.3.682","article-title":"Interferon beta in the treatment of multiple sclerosis","volume":"51","author":"Yong","year":"1998","journal-title":"Neurology"},{"key":"2022011316464495300_b42","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1212\/WNL.50.5.1294","article-title":"In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis","volume":"50","author":"Rudick","year":"1998","journal-title":"Neurology"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2249.2000.01175.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2249.2000.01175.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/120\/1\/147\/42182996\/j.1365-2249.2000.01175.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/120\/1\/147\/42182996\/j.1365-2249.2000.01175.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T07:37:55Z","timestamp":1704785875000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/120\/1\/147\/6461601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2001,12,24]]},"published-print":{"date-parts":[[2001,12,24]]}},"URL":"https:\/\/doi.org\/10.1046\/j.1365-2249.2000.01175.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2000,4]]},"published":{"date-parts":[[2000,4]]}}}